Tab Application Banner
  • Users Online: 548
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2018  |  Volume : 13  |  Issue : 4  |  Page : 259-263

Use of biologic response modifiers for the management of ocular inflammatory conditions

1 Departments of Ophthalmology, Oregon Health and Science University, Portland, OR, USA
2 Department of Ophthalmology, Oregon Health and Science University, Portland, OR, USA; Singapore National Eye Centre, Singapore; Department of Laboratory of Immunology, National Institutes of Health, National Eye Institute, Bethesda, MD, USA
3 Department of Ophthalmology; Department of Medicine, Oregon Health and Science University; Uveitis Clinic, Legacy Devers Eye Institute, Portland, OR, USA

Correspondence Address:
Dr. James T Rosenbaum
Oregon Health and Science University, 3181 SW Sam Jackson Pk Rd, L467Ad, Portland, OR 97239, USA.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injr.injr_83_18

Rights and Permissions

Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded293    
    Comments [Add]    
    Cited by others 2    

Recommend this journal